Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.

Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, Larson SM, Old LJ.

Clin Cancer Res. 2010 Nov 1;16(21):5288-95. doi: 10.1158/1078-0432.CCR-10-0700. Epub 2010 Sep 20.

2.

Farletuzumab in epithelial ovarian carcinoma.

Spannuth WA, Sood AK, Coleman RL.

Expert Opin Biol Ther. 2010 Mar;10(3):431-7. doi: 10.1517/14712591003592069. Review.

PMID:
20092424
3.

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.

Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD.

Gynecol Oncol. 2013 Nov;131(2):493-8. doi: 10.1016/j.ygyno.2013.07.080. Epub 2013 Jul 14. Review.

PMID:
23863359
4.

Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.

Bergamini A, Ferrero S, Leone Roberti Maggiore U, Scala C, Pella F, Vellone VG, Petrone M, Rabaiotti E, Cioffi R, Candiani M, Mangili G.

Expert Opin Investig Drugs. 2016 Dec;25(12):1405-1412. Review.

PMID:
27797594
5.

Farletuzumab in lung cancer.

Thomas A, Maltzman J, Hassan R.

Lung Cancer. 2013 Apr;80(1):15-8. doi: 10.1016/j.lungcan.2012.12.021. Epub 2013 Jan 26. Review.

6.

Profile of farletuzumab and its potential in the treatment of solid tumors.

Sato S, Itamochi H.

Onco Targets Ther. 2016 Mar 7;9:1181-8. doi: 10.2147/OTT.S98242. eCollection 2016. Review.

7.

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.

Vergote IB, Marth C, Coleman RL.

Cancer Metastasis Rev. 2015 Mar;34(1):41-52. doi: 10.1007/s10555-014-9539-8. Review.

PMID:
25564455
8.

Monoclonal antibodies therapies for ovarian cancer.

Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S.

Expert Opin Biol Ther. 2013 May;13(5):739-64. doi: 10.1517/14712598.2013.767328. Epub 2013 Feb 4. Review.

PMID:
23373587
9.

Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors.

Vergote I, Leamon CP.

Ther Adv Med Oncol. 2015 Jul;7(4):206-18. doi: 10.1177/1758834015584763. Review.

10.

Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.

Marchetti C, Palaia I, Giorgini M, De Medici C, Iadarola R, Vertechy L, Domenici L, Di Donato V, Tomao F, Muzii L, Benedetti Panici P.

Onco Targets Ther. 2014 Jul 10;7:1223-36. doi: 10.2147/OTT.S40947. eCollection 2014. Review.

Supplemental Content

Support Center